BrightGene Bets On Remdesivir Amid Patent Questions
Claims R&D Work Is Non-Infringing
Executive Summary
Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.
You may also be interested in...
China Planning To Ban Gene Editing Technology Exports
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
Chinese Balloon Affair To Blow Up US Health Collaboration?
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.